- Home
- MTAL vs WVE Comparison
MTAL vs WVE Comparison
Compare MTAL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- WVE
- Stock Information
- Founded
- MTAL 2021
- WVE 2012
- Country
- MTAL Jersey
- WVE Singapore
- Employees
- MTAL N/A
- WVE N/A
- Industry
- MTAL Blank Checks
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- WVE Health Care
- Exchange
- MTAL Nasdaq
- WVE Nasdaq
- Market Cap
- MTAL 997.3M
- WVE 915.6M
- IPO Year
- MTAL 2021
- WVE 2015
- Fundamental
- Price
- MTAL $12.05
- WVE $7.82
- Analyst Decision
- MTAL Hold
- WVE Strong Buy
- Analyst Count
- MTAL 4
- WVE 13
- Target Price
- MTAL $12.08
- WVE $20.15
- AVG Volume (30 Days)
- MTAL 757.6K
- WVE 1.2M
- Earning Date
- MTAL 08-09-2025
- WVE 08-07-2025
- Dividend Yield
- MTAL N/A
- WVE N/A
- EPS Growth
- MTAL N/A
- WVE N/A
- EPS
- MTAL N/A
- WVE N/A
- Revenue
- MTAL $340,736,000.00
- WVE $104,939,000.00
- Revenue This Year
- MTAL $18.41
- WVE N/A
- Revenue Next Year
- MTAL $23.55
- WVE $1.94
- P/E Ratio
- MTAL N/A
- WVE N/A
- Revenue Growth
- MTAL 114.30
- WVE N/A
- 52 Week Low
- MTAL $7.69
- WVE $5.04
- 52 Week High
- MTAL $14.93
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- MTAL 60.65
- WVE 67.70
- Support Level
- MTAL $11.94
- WVE $6.25
- Resistance Level
- MTAL $12.09
- WVE $8.13
- Average True Range (ATR)
- MTAL 0.09
- WVE 0.41
- MACD
- MTAL -0.07
- WVE 0.13
- Stochastic Oscillator
- MTAL 50.00
- WVE 92.82
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.